Antithrombotic treatment for chronic coronary syndrome: Evidence and future perspectives

Archana Kulasingam; Manan Pareek; Felice Gragnano; Morten Würtz; Kasper Pryds; Paolo Calabrò; Erik Lerkevang Grove

doi:10.1159/000537706

Antithrombotic treatment for chronic coronary syndrome: Evidence and future perspectives

Archana Kulasingam, Manan Pareek, Felice Gragnano, Morten Würtz, Kasper Pryds, Paolo Calabrò, Erik Lerkevang Grove

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Review › Forskning › peer review

Abstract

Background The clinical presentation of coronary artery disease can range from asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute coronary syndrome. Chronic coronary syndrome is a frequent condition, and secondary prevention of ischaemic events is essential. Summary Antithrombotic therapy is a key component of secondary prevention strategies, and it may vary in type and intensity depending on patient characteristics, comorbidities, and revascularisation modalities. Dual antiplatelet therapy is the default strategy in patients with chronic coronary syndrome and recent coronary stent implantation, while antiplatelet monotherapy is commonly prescribed for long-term prevention of cardiovascular events. Oral anticoagulation, in combination with antiplatelet therapy or alone, is used in patients with e.g., concomitant atrial fibrillation or venous thromboembolism. Key messages This review provides an overview of antithrombotic treatment strategies in patients with chronic coronary syndrome. Key messages from current guidelines are conveyed, and we provide future perspectives on long-term antithrombotic strategies.

Originalsprog	Engelsk
Tidsskrift	Cardiology
Sider (fra-til)	1-11
Antal sider	11
ISSN	0008-6312
DOI	https://doi.org/10.1159/000537706
Status	E-pub ahead of print - feb. 2024

Adgang til dokumentet

10.1159/000537706

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{838471d5d01d4a359960d2f3f81466d8,

title = "Antithrombotic treatment for chronic coronary syndrome: Evidence and future perspectives",

abstract = "Background The clinical presentation of coronary artery disease can range from asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute coronary syndrome. Chronic coronary syndrome is a frequent condition, and secondary prevention of ischaemic events is essential. Summary Antithrombotic therapy is a key component of secondary prevention strategies, and it may vary in type and intensity depending on patient characteristics, comorbidities, and revascularisation modalities. Dual antiplatelet therapy is the default strategy in patients with chronic coronary syndrome and recent coronary stent implantation, while antiplatelet monotherapy is commonly prescribed for long-term prevention of cardiovascular events. Oral anticoagulation, in combination with antiplatelet therapy or alone, is used in patients with e.g., concomitant atrial fibrillation or venous thromboembolism. Key messages This review provides an overview of antithrombotic treatment strategies in patients with chronic coronary syndrome. Key messages from current guidelines are conveyed, and we provide future perspectives on long-term antithrombotic strategies.",

keywords = "Antiplatelet agents, Antithrombotic drugs, Chronic coronary syndrome, Coronary artery disease",

author = "Archana Kulasingam and Manan Pareek and Felice Gragnano and Morten W{\"u}rtz and Kasper Pryds and Paolo Calabr{\`o} and Grove, {Erik Lerkevang}",

note = "S. Karger AG, Basel.",

year = "2024",

month = feb,

doi = "10.1159/000537706",

language = "English",

pages = "1--11",

journal = "Cardiology",

issn = "0008-6312",

publisher = "S. Karger AG",

}

TY - JOUR

T1 - Antithrombotic treatment for chronic coronary syndrome

T2 - Evidence and future perspectives

AU - Kulasingam, Archana

AU - Pareek, Manan

AU - Gragnano, Felice

AU - Würtz, Morten

AU - Pryds, Kasper

AU - Calabrò, Paolo

AU - Grove, Erik Lerkevang

N1 - S. Karger AG, Basel.

PY - 2024/2

Y1 - 2024/2

N2 - Background The clinical presentation of coronary artery disease can range from asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute coronary syndrome. Chronic coronary syndrome is a frequent condition, and secondary prevention of ischaemic events is essential. Summary Antithrombotic therapy is a key component of secondary prevention strategies, and it may vary in type and intensity depending on patient characteristics, comorbidities, and revascularisation modalities. Dual antiplatelet therapy is the default strategy in patients with chronic coronary syndrome and recent coronary stent implantation, while antiplatelet monotherapy is commonly prescribed for long-term prevention of cardiovascular events. Oral anticoagulation, in combination with antiplatelet therapy or alone, is used in patients with e.g., concomitant atrial fibrillation or venous thromboembolism. Key messages This review provides an overview of antithrombotic treatment strategies in patients with chronic coronary syndrome. Key messages from current guidelines are conveyed, and we provide future perspectives on long-term antithrombotic strategies.

AB - Background The clinical presentation of coronary artery disease can range from asymptomatic, through stable disease in the form of chronic coronary syndrome, to acute coronary syndrome. Chronic coronary syndrome is a frequent condition, and secondary prevention of ischaemic events is essential. Summary Antithrombotic therapy is a key component of secondary prevention strategies, and it may vary in type and intensity depending on patient characteristics, comorbidities, and revascularisation modalities. Dual antiplatelet therapy is the default strategy in patients with chronic coronary syndrome and recent coronary stent implantation, while antiplatelet monotherapy is commonly prescribed for long-term prevention of cardiovascular events. Oral anticoagulation, in combination with antiplatelet therapy or alone, is used in patients with e.g., concomitant atrial fibrillation or venous thromboembolism. Key messages This review provides an overview of antithrombotic treatment strategies in patients with chronic coronary syndrome. Key messages from current guidelines are conveyed, and we provide future perspectives on long-term antithrombotic strategies.

KW - Antiplatelet agents

KW - Antithrombotic drugs

KW - Chronic coronary syndrome

KW - Coronary artery disease

UR - http://www.scopus.com/inward/record.url?scp=85194498213&partnerID=8YFLogxK

U2 - 10.1159/000537706

DO - 10.1159/000537706

M3 - Review

C2 - 38354713

SN - 0008-6312

SP - 1

EP - 11

JO - Cardiology

JF - Cardiology

ER -

Antithrombotic treatment for chronic coronary syndrome: Evidence and future perspectives

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater